| [1] |
Bhardwaj A，Singh A，Midha V，et al.Cardiovascular implications of inflammatory bowel disease：An updated review[J].World J Cardiol，2023, 15(11)：553-570.
|
| [2] |
Song B，Bie Y，Feng H，et al.Inflammatory Factors Driving Atherosclerotic Plaque Progression New Insights[J].J Transl Int Med, 2022，10(1): 36-47.
|
| [3] |
Łykowska-Szuber L，Rychter AM，Dudek M，et al.What Links an Increased Cardiovascular Risk and Inflammatory Bowel Disease？A Narrative Review[J].Nutrients，2021，13(8)：2661-2677.
|
| [4] |
Magro F，Soares JB，Fernandes D．Venous thrombosis and prothrombotic factors in inflammatory bowel disease[J].World J Gastroenterol，2014，20(17)：4857-4872.
|
| [5] |
Pepe M，Cecere AD，Alessandro P，et al.Massive stent thrombosis during active ulcerative colitis：the tricky balance between manifest hemorrhagic and concealed thrombotic risk[J].Clin Exp Med，2018, 18(4)：481-485.
|
| [6] |
Papadimitraki ED，Ahamed M，Bunce NH.Acute myocardial infarction complicating active ulcerative colitis：a case report[J].Case Rep Cardiol, 2011，2011：876896.
|
| [7] |
Chan SS，Luben R，Bergmann MM，et al.Aspirin in the aetiology of Crohn′s disease and ulcerative colitis：a European prospective cohort study[J].Aliment Pharmacol Ther，2011，34(6)：649-655.
|
| [8] |
Ananthakrishnan AN，Higuchi LM，Huang ES，et al.Aspirin, nonsteroidal anti-inflammatory drug use，and risk for Crohn disease and ulcerative colitis：a cohort study[J].Ann Intern Med，2012，156(5)：350-359.
|
| [9] |
Kefalakes H，Stylianides TJ，Amanakis G，et al.Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs：myth or reality？[J].Eur J Clin Pharmacol，2009, 65(10)：963-970.
|
| [10] |
Hensley A，Beales IL.Use of Cyclo-Oxygenase Inhibitors Is Not Associated with Clinical Relapse in Inflammatory Bowel Disease：A Case-Control Study[J].Pharmaceuticals (Basel)，2015，8(3)：512-524.
|
| [11] |
Patel P，Gao G，Gulotta G，et al.Daily aspirin use does not impact clinical outcomes in patients with inflammatory bowel disease[J]. Inflamm Bowel Dis，2021，27(2)：236-241.
|
| [12] |
Wu H，Hu T，Hao H，et al.Inflammatory bowel disease and cardiovascular diseases：a concise review[J].Eur Heart J Open，2021，2(1): 1-9.
|
| [13] |
Feng W，Chen G，Cai D，et al.Inflammatory bowel disease and risk of ischemic heart disease：an updated meta analysis of cohort studies[J].J Am Heart Assoc，2017，6：e005892.
|
| [14] |
Jaaouani A，Ismaiel A，Popa SL，et al.Acute coronary syndromes and inflammatory bowel disease：the gut-heart connection[J].J Clin Med，2021, 10(20)：4710-4722.
|
| [15] |
抗血小板药物消化道损伤的预防和治疗中国专家共识组．抗血小板药物消化道损伤的预防和治疗中国专家共识(2012更新版)[J].中华内科杂志，2013，52(3)：264-270.
|
| [16] |
Hsu PI.New look at antiplatelet agent-related peptic ulcer：an update of prevention and treatment[J].J Gastroenterol Hepatol，2012，27(4): 654-661.
|
| [17] |
Patel SH，Rachchh MA，Jadav PD.Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease[J].Indian J Pharmacol，2012，44(6)：744-748.
|
| [18] |
Lanas A，Wu P，Medin J，et al.Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis[J].Clin Gastroenterol Hepatol，2011，9(9)：762-768，e766.
|
| [19] |
Amsterdam EA，Wenger NK，Brindis RG，et al.2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes：executive summary：a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].Circulation，2014，130(25)：2354-2394.
|
| [20] |
Kolh P，Windecker S．ESC/EACTS myocardial revascularization guidelines 2014[J].Eur Heart J，2014，35(46)：3235-3236.
|
| [21] |
中华医学会心血管病学分会动脉粥样硬化与冠心病学组．冠心病双联抗血小板治疗中国专家共识[J].中华心血管病杂志，2021, 49(5)：432-454.
|
| [22] |
Urban P，Mehran R，Colleran R，et al.Defining high bleeding risk in patients undergoing percutaneous coronary intervention[J].Circulation, 2019，140(3)：240-261.
|
| [23] |
Nemalidinne KV，Vanteru ASKR，Goel A，et al.Acute myocardial infarction complicating acute ulcerative colitis：A clinical conundrum [J].Clin Case Rep，2023，11(10)：e8024.
|
| [24] |
Yang M，Ye Z，Mei L，et al.Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis[J].Eur J Clin Pharmacol，2021，77(12)：1815-1823.
|
| [25] |
Storey RF，Husted S，Harrington RA，et al.Inhibition of platelet aggregation by AZD6140，a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes [J].J Am Coll Cardiol，2007，50(19)：1852-1856.
|
| [26] |
Katus H，Mahaffey KW，Scirica BM，et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes[J].N Engl J Med，2009，361(11)：1045-1057.
|
| [27] |
Vranckx P，Valgimigli M，Juni P，et al.Ticagrelor plus aspirin for 1 month，followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months，followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent：A multicentre, open-label，randomised superiority trial[J].Lancet，2018，392(10151)：940-949.
|
| [28] |
Valgimigli M，Campo G，Monti M，et al.Short versus long term duration of dual antiplatelet therapy after coronary stenting：a randomized multicenter trial[J].Circulation，2012，125(16): 2015-2026.
|
| [29] |
Kim BK，Hong SJ，Cho YH，et al.Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome：the TICO randomized clinical trial[J].JAMA，2020，323(23)：2407-2416.
|
| [30] |
Costa F，Tijssen JG，Ariotti S，et al.Incremental value of the CRUSADE, ACUITY, and HAS BLED risk scores for the prediction of hemorrhagic events after coronary stent implantation in patients undergoing long or short duration of dual antiplatelet therapy[J].J Am Heart Assoc，2015，4(12): e002524.
|
| [31] |
Palmerini T，Della Riva D，Benedetto U，et al.Three, six，or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes：an individual patient data pairwise and network meta analysis of six randomized trials and 11473 patients[J].Eur Heart J，2017，38(14)：1034-1043.
|
| [32] |
Escaned J，Cao D，Baber U，et al.Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR[J].Eur Heart J，2021，42(45)：4624-4634.
|
| [33] |
Costa F，van Klaveren D，James S，et al.Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score：a pooled analysis of individual-patient datasets from clinical trials[J].Lancet，2017，389(10073)：1025-1034.
|
| [34] |
Gurbel P，Hamm CW，Henry T，et al.Ticagrelor alone vs.ticagrelor plus aspirin following percutaneous coronary intervention in patients with non ST segment elevation acute coronary syndromes：TWILIGHT ACS[J]. Eur Heart J，2020，41(37): 3533-3545.
|